ArticleToxicology2025
Utilization of the CometChip assay for detecting PAH-induced DNA bulky adducts in a 3D primary human bronchial epithelial cell model.
Article in Toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Polycyclic aromatic hydrocarbons (PAHs), which are formed during incomplete combustion of organic materials, may cause cancer through DNA damage mediated by formation of bulky DNA adducts from PAH reactive metabolites. The airway epithelium is a primary route of exposure for inhaled PAHs, and primary human bronchial epithelial cells (HBECs) in monolayer or organotypic cultures offer a more realistic testing scenario compared to traditional cell lines. However, lack of knowledge about their capacity to mediate DNA damage through generation of reactive chemical intermediates limits their use in quantitative studies for toxicity assessment or predictive modeling compared to in vivo studies. In this study, we explored the capacity of monolayer HBECs to generate DNA damage from metabolic activation of benzo[a]pyrene (BAP, 0.001 - 1 µg/mL, 24 h) using the high-throughput CometChip assay in comparison to HepG2 and MEF cells, as positive and negative metabolic controls, respectively. The CometChip assay was further adapted to evaluate DNA damage in HBECs cultured at the air-liquid interface (ALI) exposed to BAP (0.04-1.14 µg/cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.